TABLE 5.
Characteristics of Patients Who Underwent HBV‐RNA Quantification (Liverpool Cohort)
| Characteristics | Total | HBV RNA Detected | P Value | ||
|---|---|---|---|---|---|
| Yes (n = 41) | No (n = 60) | ||||
| Age, median years (IQR) | 36 (29, 43) | 37 (30, 42) | 36 (29, 44) | 0.9948 | |
| Female, n (%) | 40 (39.6) | 22 (55.0) | 18 (45.0) | 0.0228* | |
| Male, n (%) | 61 (60.4) | 19 (31.1) | 42 (68.9) | — | |
| Ethnicity, n (%) | |||||
| Asian | 53 (52.5) | 29 (54.7) | 24 (45.3) | 0.0042 † | |
| Black African | 32 (31.7) | 6 (18.8) | 26 (81.2) | — | |
| White | 16 (15.8) | 6 (37.5) | 10 (62.5) | — | |
| HBeAg, n (%) | |||||
| Negative | 76 (75.2) | 22 (28.9) | 54 (71.1) | <0.0001 ‡ | |
| Positive | 25 (24.8) | 19 (76.0) | 6 (24.0) | — | |
| On antiviral therapy, n (%) | 53 (52.5) | 23 (43.4) | 30 (56.6) | 0.1713 § | |
| Duration of therapy, median years (IQR) || | 2.2 (1.1, 4.5) | 1.3 (0.8, 3.5) | 3.9 (1.6, 6.8) | 0.0494 | |
| HBV DNA (Aptima HBV), median log10 IU/mL | 2.4 (<1, 3.7) | 3.6 (2.4‐4.6) | <1 (<1, 2.7) | <0.0001 | |
*
Female versus male.
†
Asian versus non‐Asian.
‡
HBeAg‐positive versus HBeAg‐negative.
§
On antiviral therapy versus untreated.
||
Among treated patients.